The 2025 ASCO Genitourinary Cancers Symposium will provide expert, multidisciplinary perspectives on the latest clinical and scientific advances in the field. View the official Meeting Announcement for a message from the Chair, Program Highlights, Featured Sessions information, and how to register.
Program At A Glance
Thursday, February 13, 2025
| 7:00 AM- 8:00 AM |
Complimentary Continental Breakfast |
| 7:00 AM- 6:45 AM |
Exhibits Open |
| 8:00 AM- 9:40 AM |
Oral Abstract Session A: Prostate CancerKosj Yamoah, MD, PhD—Chair H. Lee Moffitt Cancer Center and Research InstituteChanning Judith Paller, MD—Chair The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPeter Hoskin, MD, FRCP, FRCR Welcome of the Day ABSTRACT 308: Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials. ABSTRACT 309: Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs). Edwin Posadas, MD, FACP ABSTRACT LBA18: Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. ABSTRACT 20: Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). Tanya B. Dorff, MD |
| 9:40 AM-10:10 AM | Break |
| 10:10 AM-11:25 AM | Understanding Radioligand Therapies for Advanced Prostate CancerAngela Y Jia, MD, PhD—Chair University Hospitals Seidman Cancer Center and Case Western Reserve UniversityDevaki Shilpa Surasi, MBBS—Chair University of Texas at MD Anderson Cancer Center PSMA-Based Therapy in Advanced Disease: Touching on Combination SequencingWilliam Kevin Kelly, DO Thomas Jefferson University Hospital Beyond PSMA-Targeted Agents for Advanced Disease Danny Mena Cortes ABSTRACT 17: Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901). ABSTRACT 16: Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177Lu-PSMA-617. Panel Question and Answer |
| 11:25 AM-12:45 PM | Poster Session A: Prostate Cancer With Complimentary Boxed Lunch |
| 11:25 AM-12:45 PM | Trials in Progress Poster Session A: Prostate Cancer With Complimentary Boxed Lunch |
| 11:35 AM-12:35 PM | Trainee and Early-Career Networking LuncheonView the networking faculty list here |
| 12:45 PM-2:00 PM | Case-Based Session: Management of Biochemical Recurrence After Radiation Therapy for Localized Prostate CancerMichael Cookson, MD, MMHC, FACS—Chair University of Oklahoma College of MedicineBarbara Jereczek-Fossa, MD—Chair IEO European Institute of Oncology IRCCSMichael Cookson, MD, MMHC, FACS University of Oklahoma College of Medicine Recurrence After Radiation Therapy: Evaluation, Management, and Outcomes Heather H. Cheng, MD, PhD Juanita Crook, FRCPC Thomas Polascik, MD Ashley Ross, MD, PhD Alicia K. Morgans, MD, MPH, FASCO Panel Question and Answer |
| 2:15 PM-3:05 PM | KeynotePeter Hoskin, MD, FRCP, FRCR – Chair Mount Vernon Cancer Centre, University College London, and University of Manchester Introduction of Dr. DahutWilliam L. Dahut, MD American Cancer Society Creative Innovation: Driving Science to Improve Patient-Centered CareQuestion and Answer |
| 3:05 PM- 3:30 PM |
Break |
| 3:30 PM- 4:45 PM |
Case-Based Session: Evolving Landscape of the Management of Oligometastatic DiseaseKaren E. Hoffman, MD, MHSc, MPH—Chair The University of Texas MD Anderson Cancer CenterNicholas David James—Chair Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation TrustABSTRACT 15: World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration. First Author: Chad Tang, MD, BS, MS Kenneth L. Gage, MD, PhD Brandon A. Mahal, MD Kasmintan A. Schrader, PhD, MBBS Sandy Srinivas, MD Panel Question and Answer |
| 5:00 PM- 5:45 PM |
Rapid Oral Abstract Session A: Prostate CancerMarjory Jolicoeur, MD, PhD, FRCPC—Chair Hôpital Charles-LeMoyneABSTRACT 310: Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial. – 5 minutes First Author: Abdenour Nabid, MDABSTRACT 311: Gut health and prostate cancer: The influence of a specific phytochemical-rich food capsule plus or minus a probiotic/prebiotic blend on symptoms and progression—A randomised, double-blind placebo-controlled trial. – 5 minutes First Author: Robert J. Thomas, MD ABSTRACT 312: A high omega-3, low omega-6 diet with fish oil for men with prostate cancer on active surveillance: The CAPFISH-3 randomized clinical trial. – 5 minutes ABSTRACT 21: Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform. – 5 minutes ABSTRACT 22: Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9). – 5 minutes ABSTRACT LBA138: Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study. – 5 minutes Panel Question and Answer |
| 5:45 PM-6:45 PM | Poster Session A (Continued) With Complimentary Wine and Cheese Reception |
| 5:45 PM-6:45 PM | Trials in Progress Poster Session A (Continued) With Complimentary Wine and Cheese Reception |
| 6:00 PM-6:45 PM | Poster Walks: Prostate CancerMarjory Jolicoeur, MD, PhD, FRCPC Hôpital Charles-LeMoyne Poster Walk LeaderChanning Judith Paller, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Poster Walk Leader |
| 6:00 PM- 6:45 PM |
Women’s Networking Reception |
Friday, February 14, 2025
| 7:00 AM-8:10 AM | Complimentary Continental Breakfast |
| 7:00 AM-5:45 PM | Exhibits Open |
| 8:10 AM-9:45 AM | Oral Abstract Session B: Urothelial CarcinomaElizabeth A. Guancial, MD—Chair Florida Cancer Specialists & Research InstituteNicholas I. Simon, MD, MSc—Chair National Cancer InstituteAndrea B Apolo, MD Welcome of the Day ABSTRACT 658: Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274. ABSTRACT 659: Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. – 10 minutes Elizabeth R. Plimack, MD, FASCO, MS ABSTRACT 661: Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma. – 10 minutes ABSTRACT 665: Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. – 10 minutes Scot Anthony Niglio, MD, MS Panel Question and Answer |
| 9:45 AM-10:15 AM | Break |
| 10:15 AM-11:30 AM | Case-Based Session: Non-Muscle Invasive Bladder Cancer: Exploring Therapies Beyond Bacillus Calmette-GuérinBrian Christopher Baumann, MD—Chair Springfield ClinicBogdana Schmidt, MD, MPH—Chair University of Utah The Changing World of Non-Muscle Invasive Bladder CancerCase Presentation Girish S. Kulkarni, MD, PhD Mark Tyson, MPH Tracy L Rose, MD Panel Question and Answer |
| 11:30 AM-12:45 PM | Poster Session B: Urothelial Carcinoma With Complimentary Boxed Lunch |
| 11:30 AM-12:45 PM | Trials in Progress Poster Session B: Urothelial Carcinoma With Complimentary Boxed Lunch |
| 11:40 AM-12:35 PM | Breakout Session: Emerging Trends and Advances in Germ Cell TumorsAditya Bagrodia, MD—Chair University of California, San Diego HealthAnja Lorch, MD—Chair Universitätsspital ZürichNabil Adra, MD Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center High-Dose Chemotherapy in Testicular Cancer: Current Evidence and Clinical Indications Axel Heidenreich, MD Darren R. Feldman, MD Panel Question and Answer |
| 12:45 PM-2:00 PM | The ABCs of ADCs: Unleashing the Power of Antibody-Drug Conjugates in Advanced Bladder CancerKent William Mouw, MD, PhD—Chair Dana-Farber Cancer Institute, Brigham and Women’s HospitalBenjamin Garmezy, MD—Chair Sarah Cannon Research InstituteDi Maria Jiang, MD, MSc, FRCPC Princess Margaret Hospital, University Health Network Targeting Bladder Cancer With Antibody Drug Conjugates Funda Meric-Bernstam, MD, FASCO Daniel Castellano, MD Terence W. Friedlander, MD ABSTRACT 657: Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study. Panel Question and Answer |
| 2:00 PM-2:30 PM | Break |
| 2:30 PM-3:45 PM | Panning for Gold: The Role of ctDNA as a Biomarker for Bladder CancerBernadett Szabados, MBBS—Chair Barts Cancer CentreJoaquim Bellmunt, MD—Chair Dana-Farber Cancer InstituteRoger Li, MD H. Lee Moffitt Cancer Center and Research Institute Capturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease? Alexander William Wyatt, PhD Nimira S. Alimohamed, FRCPC Gillian Vandekerkhove, PhD, MSc Panel Question and Answer |
| 4:00 PM-4:45 PM | Rapid Oral Abstract Session B: Urothelial CarcinomaKatie S. Murray, DO, FACS, MS—Chair Department of Urology, NYU Langone HealthABSTRACT 662: A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1. First Author: Gopa Iyer, MDABSTRACT 663: Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. First Author: Funda Meric-Bernstam, MD, FASCO ABSTRACT 664: EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). ABSTRACT 666: Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study. ABSTRACT 667: A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4). ABSTRACT 815: A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2). Panel Question and Answer |
| 4:45 PM-5:45 PM | Poster Session B (Continued) With Complimentary Wine and Cheese Reception |
| 4:45 PM-5:45 PM | Trials in Progress Poster Session B (Continued) With Complimentary Wine and Cheese Reception |
| 5:00 PM-5:45 PM | Poster Walks: Urothelial CarcinomaElias Chandran, FRACP, MBBS National Cancer Institute Poster Walk LeaderArmine Smith, MD Johns Hopkins University School of Medicine Poster Walk Leader |
Saturday, February 15, 2025
| 7:00 AM-8:10 AM | Complimentary Continental Breakfast |
| 7:10 AM-8:10 AM | Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers |
| 7:10 AM-8:10 AM | Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers |
| 8:10 AM-9:45 AM | Oral Abstract Session C: Renal Cell CancerArpita Desai, MD—Chair University of California, San FranciscoDaniel Shapiro—Chair University of Wisconsin-MadisonTodd Matthew Morgan, MD Welcome of the Day ABSTRACT 438: Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. ABSTRACT 439: Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial. ABSTRACT 440: KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC). Tian Zhang, MD, MHS ABSTRACT 618: Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results. Clint Cary, MD, MBA, MPH Panel Question and Answer |
| 9:45 AM-10:15 AM | Break |
| 10:15 AM-11:30 AM | Biomarkers and Adjuvant Therapy for Renal Cell Carcinoma: Current State and Future DirectionsShuchi Gulati, MD, MS, FACP—Chair University of California, Davis Comprehensive Cancer CenterAxel Bex, MD, PhD—Chair Royal Free London NHS Foundation TrustABSTRACT 437: Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214. First Author: Wenxin Xu, MD Simpa Samuel Salami, MD, MPH Samra Turajlic, MD, PhD Laurence Albiges, MD, PhD Panel Question and Answer |
| 11:30 AM-12:45 PM | Poster Session C (Continued) With Complimentary Boxed Lunch |
| 11:30 AM-12:45 PM | Trials in Progress Poster Session C (Continued) With Complimentary Boxed Lunch |
| 11:40 AM-12:35 PM | Women in Genitourinary Cancers Networking LuncheonView the networking faculty list here |
| 11:45 AM-12:30 PM | Poster Walks: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral CancersBrittney Cotta, MD University of Texas MD Anderson Cancer Center Poster Walk LeaderShuchi Gulati, MD, FACP, MS UC Davis Comprehensive Cancer Center Poster Walk Leader |
| 12:45 PM- 1:30 PM |
Rapid Oral Abstract Session C: Renal Cell CancerBrittney Cotta, MD—Chair University of Texas MD Anderson Cancer CenterABSTRACT 441: Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study. First Author: Toni K. Choueiri, MD, FASCOABSTRACT 442: Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191). First Author: Xiaofan Lu, PhD ABSTRACT 443: Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study. ABSTRACT 444: Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO). ABSTRACT 1: EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma. Panel Question and Answer |
| 1:45 PM-3:00 PM | Case-Based Session: Failure of Immunotherapy in Renal Cell Cancer: What’s Next?Leslie K. Ballas, MD—Chair Cedars-Sinai Medical CenterKathryn Hacker Gessner, MD, PhD—Chair UNC School of MedicineMaria T. Bourlon, MD, MSc, FASCO Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Medical Oncology Matthew T Campbell, MD, MS Raquibul Hannan, MD, PhD Viraj A. Master, MD, PhD Panel Question and Answer |
Reviews
There are no reviews yet.